Prof Thomas Powles talks to ecancer about the first phase II results from the NORSE study. Erdafitinib (ERDA) or ERDA Plus Cetrelimab (CET) for Patients With Metastatic or Locally Advanced Urothelial Carcinoma (mUC) and Fibroblast Growth Factor Receptor Alterations (FGFRa).
He begins by explaining that metastatic urothelial cancer is associated with a poor outcome, particularly in patients who are not eligible for cisplatin based therapy. The question that has been asked is whether erdafitinib or erdafitinib with PD-1 inhibitor cetrelimab has significant efficacy in frontline treatment.
Prof Powles then talks about how he believes the Norse trial has the potential to change the way we think about urothelial cancer with response rates in the high 60% for the combination.
He concludes by stating the next steps for the Norse trial are to continue enrolment and to encourage enrolment, explaining that personalised therapy trials are difficult to do, particularly when only 1 in 4 patients are eligible.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.